EP0948325A2 - Nouveau traitement - Google Patents

Nouveau traitement

Info

Publication number
EP0948325A2
EP0948325A2 EP97953793A EP97953793A EP0948325A2 EP 0948325 A2 EP0948325 A2 EP 0948325A2 EP 97953793 A EP97953793 A EP 97953793A EP 97953793 A EP97953793 A EP 97953793A EP 0948325 A2 EP0948325 A2 EP 0948325A2
Authority
EP
European Patent Office
Prior art keywords
lamotrigine
migraine
pharmaceutically acceptable
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97953793A
Other languages
German (de)
English (en)
Inventor
John Morris SmithKline Beecham Pharm. EVANS
Andrew SmithKline Beecham Pharm PARSONS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0948325A2 publication Critical patent/EP0948325A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

L'invention concerne un procédé de traitement ou de prévention de la migraine chez l'humain. Le procédé consiste à administrer à un patient souffrant de la migraine une quantité effective de lamotrigine ou un sel pharmaceutiquement acceptable dudit produit.
EP97953793A 1996-12-12 1997-12-09 Nouveau traitement Withdrawn EP0948325A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9625795 1996-12-12
GBGB9625795.1A GB9625795D0 (en) 1996-12-12 1996-12-12 Novel treatment
PCT/EP1997/006971 WO1998025594A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Publications (1)

Publication Number Publication Date
EP0948325A2 true EP0948325A2 (fr) 1999-10-13

Family

ID=10804309

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97953793A Withdrawn EP0948325A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Country Status (5)

Country Link
EP (1) EP0948325A2 (fr)
JP (1) JP2001510461A (fr)
CA (1) CA2274858A1 (fr)
GB (1) GB9625795D0 (fr)
WO (1) WO1998025594A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213565B1 (pl) * 2002-07-29 2013-03-29 Glaxo Group Ltd Preparat o przedluzonym uwalnianiu zawierajacy lamotrygine
EP1438956A1 (fr) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Dérivés alpha-aminoamides en tant qu'agents antimigraine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9825594A2 *

Also Published As

Publication number Publication date
WO1998025594A3 (fr) 1998-09-17
CA2274858A1 (fr) 1998-06-18
JP2001510461A (ja) 2001-07-31
WO1998025594A2 (fr) 1998-06-18
GB9625795D0 (en) 1997-01-29

Similar Documents

Publication Publication Date Title
US5849763A (en) Use of levobupivacaine as an anesthetic agent
EP0173848A2 (fr) Composés benzopyranniques pour utilisation dans le système cardio-vasculaire
JPS6143113A (ja) 医薬組成物
US4891380A (en) Novel treatment
EP0821588B1 (fr) Levobupivacaine et son utilisation comme anesthesique chez la femme enceinte
US5049588A (en) Novel treatment for ischemia using an aminotetralin
IE83342B1 (en) Use of a 5-HT4-receptor antagonists in the treatment of atrial fibrillation, including the prevention of stroke
WO1998025594A2 (fr) Nouveau traitement
CA2241856C (fr) Agent pour prophylaxis et traitement s'appliquant aux complications de diabetes
ES2235896T3 (es) Uso de riluzol para el tratamaiento de la esclerosis multiple.
US5162375A (en) Treatment of neuronal degeneration with 5HT1A agonists
US4654372A (en) Method for using verapamil for treating stroke
JP2001515479A (ja) 偏頭痛治療におけるレボブピバカインまたはロピバカインの使用
US5496823A (en) Pharmaceutical composition for increasing bladder capacity
EP0301713A2 (fr) Dérivés du chromane pour le traitement de l'hypertension pulmonaire
CA2074039C (fr) Preparation medicamenteuse antihypertensive
KR20010021796A (ko) 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
CN115475165B (zh) 马来酸茚达特罗在出血性脑损伤相关疾病中的应用
WO2000037082A1 (fr) Utilisation d'antagonistes du recepteur 5-ht7 pour le traitement de la degenerescence neuronale due a des accidents ischemiques
WO2007000771A2 (fr) Derives de la quinazolinone fondue et leurs utilisations
CA2073117A1 (fr) Medicament diminuant la concentration des plaquettes sanguines
KR20010071893A (ko) 치료 방법
JP2003504396A (ja) マクロライド化合物の新規用途
KR100413717B1 (ko) 레보부피바카인및임산부의마취제로서그것의용도
WO2003051347A1 (fr) Utilisation d'antagonistes de recepteurs d'urokinase afin de moduler les blessures de reperfusion ischemique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20001108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010519

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023067

Country of ref document: HK